[Insulin therapy using a portable pump in children. Apropos of a pediatric experience]

M C Wieliczko1, C H De Menibus, E Mallet

  • 1Centre Hospitalo-Universitaire, Hôpital Charles Nicolle, Rouen.

Annales De Pediatrie
|November 1, 1992
PubMed

Insights

Insulin pumps offer an alternative for pediatric patients with insulin-dependent diabetes mellitus when conventional therapies fail. While severe hypoglycemia and ketoacidosis were rare, significant metabolic control improvements were not consistently observed long-term.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Medical Device Technology

Background:

  • Insulin-dependent diabetes mellitus (IDDM) requires intensive management.
  • Insulin pumps represent a continuous subcutaneous insulin infusion therapy option.
  • Evaluating long-term efficacy and safety in pediatric populations is crucial.

Purpose of the Study:

  • To report on the experience with insulin pump therapy in pediatric patients with IDDM.
  • To assess the long-term metabolic control and adverse events associated with insulin pump use.
  • To determine the overall efficacy of insulin pumps as a treatment alternative.

Main Methods:

  • Retrospective analysis of 17 pediatric patients with IDDM treated with insulin pumps.
  • Follow-up data collected for up to four years for seven patients.
  • Monitoring of metabolic control (e.g., HbA1c), hypoglycemia, ketoacidosis, and ketosis events.

Main Results:

  • Significant metabolic control improvement observed in only 4 of 17 patients, limited to the first year.
  • Overall improvement in metabolic control was not statistically significant across the cohort.
  • Severe hypoglycemia (0.27/patient-year) and ketoacidosis (0.08/patient-year) were rare.
  • Transient ketosis was the most common adverse event, often linked to technical issues and requiring patient education.

Conclusions:

  • Insulin pump therapy can be a viable alternative for pediatric IDDM patients unresponsive to conventional treatments.
  • Long-term significant metabolic control benefits may not be universally achieved.
  • Patient education is critical for managing adverse events like transient ketosis and technical problems.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...